Olr.cmeenterprise.com

Treating Nicotine Dependence Among Patients With Mental Health or Addictive Disorders Full Reference List 1. Amering M, Bankier B, Berger P, Griengl H, Windhaber J, Katschnig H. Panic disorder and cigarette smoking behavior. Compr Psychiatry. 1999;40(1):35-38. Breslau N, Novak SP, Kessler RC. Daily smoking and the subsequent onset of psychiatric disorders. Psychol Med. 2004;34(2):323-333. Brown RA, Kahler CW, Niaura R, et al. Cognitive-behavioral treatment for depression in smoking cessation. J Consult Clin Psychol. 2001;69(3):471-480. Burling TA, Salvio MA, Seidner AL, Ramsey TG. Cigarette smoking in alcohol and cocaine abusers. J Subst Abuse. 1996;8(4):445-452. Centers for Disease Control and Prevention. Cigarette smoking among adults--United States, 2006. MMWR Morb Mortal Wkly Rep. 2007;56(44):1157-1161. Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis. 2006;3(2):A42. Cooney NL, Cooney JL, Perry BL, et al. Smoking cessation during alcohol treatment: a randomized trial of combination nicotine patch plus nicotine gum. Addiction. 2009;104(9):1588-1596. Ebbert JO, Burke MV, Hays JT, Hurt RD. Combination treatment with varenicline and nicotine replacement therapy. Nicotine Tob Res. 2009;11(5):572-576. Evins AE, Cather C, Deckersbach T, et al. A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. J Clin Psychopharmacol. 2005;25(3):218-225. FDA. Information for Healthcare Professionals: Varenicline (marketed as Chantix) and Bupropion (marketed as Zyban, Wellbutrin, and generics). FDA ALERT [7/1/2009]: Available at: Accessed May 14, 2013. Fiore MC, Jaen RC, Baker TB, et al. Treating Tobacco Use and Dependence: 2008 Update. Rockville, MD: US Department of Health and Human Services. Public Health Service; 2008. George TP, Vessicchio JC. Nicotine addiction and other psychiatric disorders Psychiatric Times. 2001;18(2). Grant BF, Hasin DS, Chou SP, Stinson FS, Dawson DA. Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry. 2004;61(11):1107-1115. Gunnell D, Irvine D, Wise L, Davies C, Martin RM. Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ. 2009;339:b3805. Hays JT, Hurt RD, Decker PA, Croghan IT, Offord KP, Patten CA. A randomized, controlled trial of bupropion sustained-release for preventing tobacco relapse in recovering alcoholics. Nicotine Tob Res. 2009;11(7):859-867. Heiligenstein E, C. R, Foulds J, Tedeschi G, Bjornson W. Are the 5A's enough?: tobacco dependence treatment for smokers with mental illness. Paper presented at: 2007 National Conference on Tobacco or Health; October 24-26, 2007; Minneapolis, MN. Heiligenstein E, Smith SS. Smoking and mental health problems in treatment-seeking university students. Nicotine Tob Res. 2006;8(4):519-523. Hertzberg MA, Moore SD, Feldman ME, Beckham JC. A preliminary study of bupropion sustained-release for smoking cessation in patients with chronic posttraumatic stress disorder. J Clin Psychopharmacol. 2001;21(1):94-98. Hughes JR. Depression during tobacco abstinence. Nicotine Tob Res. 2007;9(4):443-446. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2007(1):CD000031. Johnson BA, Ait-Daoud N, Akhtar FZ, Javors MA. Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers: a randomized controlled trial. Arch Intern Med. 2005;165(14):1600-1605. Johnson JL. Tobacco control in the context of mental illness and addictions: reviewing the evidence. Visions: BC's Mental Health and Addictions Journal. 2007;3(4):6-7. Kalman D, Kahler CW, Garvey AJ, Monti PM. High-dose nicotine patch therapy for smokers with a history of alcohol dependence: 36-week outcomes. J Subst Abuse Treat. 2006;30(3):213-217. Mann-Wrobel MC, Bennett ME, Weiner EE, Buchanan RW, Ball MP. Smoking history and motivation to quit in smokers with schizophrenia in a smoking cessation program. Schizophr Res. 2011;126(1-3):277-283. McDonald C, Sheppard N. Smoking in chronic psychiatric illness:is it worth it? Psychiatric Bulletin. 1996;20:533-535. McFall M, Saxon AJ, Malte CA, et al. Integrating tobacco cessation into mental health care for posttraumatic stress disorder: a randomized controlled trial. JAMA. 2010;304(22):2485-2493. McFall M, Saxon AJ, Thompson CE, et al. Improving the rates of quitting smoking for veterans with posttraumatic stress disorder. Am J Psychiatry. 2005;162(7):1311-1319. Moss TG, Sacco KA, Allen TM, Weinberger AH, Vessicchio JC, George TP. Prefrontal cognitive dysfunction is associated with tobacco dependence treatment failure in smokers with schizophrenia. Drug Alcohol Depend. 2009;104(1-2):94-99. Niaura R, Britt D, Borrelli B, Shadel W, Abrams D, Goldstein M. History and symptoms of depression among smokers during a self-initiated quit attempt. Nicotine Tob Res. 1999;1(3):251-257. O'Malley SS, Cooney JL, Krishnan-Sarin S, et al. A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation. Arch Intern Med. 2006;166(6):667-674. Peters EN, Hughes JR. The day-to-day process of stopping or reducing smoking: a prospective study of self-changers. Nicotine Tob Res. 2009;11(9):1083-1092. Piper ME, Cook JW, Schlam TR, Jorenby DE, Baker TB. Anxiety diagnoses in smokers seeking cessation treatment: relations with tobacco dependence, withdrawal, outcome and response to treatment. Addiction. 2011;106(2):418-427. Prochaska J, Hall S, Tsoh J, et al. Treating tobacco dependence in clinically depressed smokers: effect of smoking cessation on mental health functioning. Am J Public Health. 2008;98(3):446-448. Quattrocki E, Baird A, Yurgelun-Todd D. Biological aspects of the link between smoking and depression. Harv Rev Psychiatry. 2000;8(3):99-110. Smith RC, Lindenmayer JP, Davis JM, et al. Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder. Schizophr Res. 2009;110(1-3):149-155. Strasser K, Moeller-Saxone K, Meadows G, Hocking B, Stanton J, Kee P. Smoking cessation in schizophrenia. General practice guidelines. Aust Fam Physician. 2002;31(1):21-24. Thorsteinsson HS, Gillin JC, Patten CA, et al. The effects of transdermal nicotine therapy for smoking cessation on depressive symptoms in patients with major depression. Neuropsychopharmacology. 2001;24(4):350-358. Tobacco Cessation Leadership Network. Bringing Everyone Along Resource Guide. Portland, Oregon: Oregon Health & Science University Smoking Cessation Center; 2008. Tsoh JY, Chi FW, Mertens JR, Weisner CM. Stopping smoking during first year of substance use treatment predicted 9-year alcohol and drug treatment outcomes. Drug Alcohol Depend. 2011;114(2-3):110-118. Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev. 2010(6):CD007253. Zevin S, Benowitz NL. Drug interactions with tobacco smoking. An update. Clin Pharmacokinet. 1999;36(6):425-438.

Source: http://olr.cmeenterprise.com/8414/Resources/References/ResourcesLevel/References_FINAL.PDF